AI-curated news for your industry

SFA Therapeutics co-founder and CEO Ira Spector, a veteran with 30 years of industry experience and involvement in over 500 clinical trials, is betting on a 'fourth-generation microbiome' platform. The platform uses metabolites produced by bacteria in the human body to modulate immunity and has received FDA IND clearance for its NASH candidate SFA-001N. This article tells the story of its journey from a chance lunch meeting in 2015 to now having six drug candidates targeting 85 chronic inflammation targets, and his persistence in addressing unmet medical needs behind his 'two failed retirements.'

Christina Mack, Chief Scientific Officer of IQVIA Real-World Solutions, states that the COVID-19 pandemic forced public health practices to unfold in unprecedented ways, particularly in professional sports settings. Her research with the NFL and NBA has revealed key information on virus transmission, mitigation measures, and vaccine effectiveness. She believes that with richer data sources and advances in analytical technology, real-world data (RWD) holds immense potential in rare disease research, elderly patients with comorbidities, and patient experience assessment, placing the industry at the forefront of breakthrough learning.

The menopause healthcare field has shifted from a niche topic to an investment hotspot in recent years. Evernow founder Alicia Jackson discovered that early menopause is linked to a higher risk of premature death and is determined to help women extend their healthy lifespans through telemedicine and hormone therapy. The company has secured $28.5 million in Series A funding and serves approximately 150,000 women.

Treatment for acute liver injury often reaches critical decision points. Dr. Norman L. Sussman, Chief Medical Officer of Durect Corp., shares his journey from South Africa to the United States, from academia to industry, and discusses the progress of the company's candidate drug, larsucosterol, in a Phase 2b clinical trial, which has the potential to become the first approved treatment for severe alcohol-associated hepatitis.

As one of the world's most prolific inventors, Stephen Quake leads a lab at Stanford University and serves as the head of science at the Chan Zuckerberg Initiative. Inspired by his wife's prenatal testing experience, he developed non-invasive prenatal testing, saving countless lives. Now, he oversees CZI's scientific strategy, focusing on cellular mysteries and disease prevention through research institutes, funding, and open-source software, with the goal of ending all diseases by 2099.

Omega Therapeutics' CEO, Mahesh Karande, states that MYC gene overexpression is present in most human cancers and is the 'holy grail target' in oncology. The company's OTX-2002 is a first-in-class mRNA epigenetic controller designed to downregulate MYC expression and is currently in Phase 1/2 clinical trials.

Evelina Vågesjö, co-founder and CEO of Ilya Pharma, is dedicated to expanding bacteria-enabled technology from wound treatment to cancer supportive care. The company's lead candidate drug, ILP100-Topical, has entered a pivotal Phase II study, while also developing ILP100-Oral for the treatment of colitis in cancer patients following checkpoint inhibitor therapy.

Sana Alajmovic, co-founder and CEO of Sigrid Therapeutics, went from being a refugee of the Bosnian War to a medical technology entrepreneur, now tackling diabetes prevention with SiPore21.

Cresilon founder Joe Landolina, from his teenage chemistry experiments in a vineyard laboratory, discovered a gel material derived from algae that can instantly adhere to human tissue. The technology has been used in the veterinary product Vetigel and is seeking FDA approval for human use. The company recently signed a cooperative research and development agreement with the Department of Defense to explore treatment for battlefield traumatic brain injury, while completing a $25 million funding round to expand production.

After retiring at 40, Rami Elghandour rethought his life due to the pandemic, joining CAR-T cell therapy company Arcellx as Chairman and CEO in 2021, leading the company through its IPO, and dedicating himself to developing cancer therapies with the potential to "change the world."